Histologic assessment of GVHD in BMS (15 × 10⁶ spleen cells) recipients on day 28 (PBS, TBI group) and day 48 (KGF, Cy/TBI group) after allogeneic BMT. H&E-stained cryosections of spleen, liver, colon, and lung of a representative mouse taken from the indicated treatment groups at these time points show that KGF can abrogate GVHD-induced manifestation in the liver and lung and moderately so in the spleen and colon (original magnification × 100; resolution power, 40× objective lens).